Discover and read the best of Twitter Threads about #dishmancarbogenamcis

Most recents (2)

#DishmanCarbogenAmcis Q3 FY22 concall highlights 💊💊

Like & Retweet for better reach !

1. They have had a very strong quarter - especially in CRAMS where the pipeline continues to be very strong.
2. They are seeing good interest and strong growth in the Vitamin D analogues.

3. The cholesterol business is stable and the disinfectant business is seeing increased interest from customers.
4. They have seen a rapid rise in transportation and logistics costs. There are also price rises in Central Europe for basic utilities like electricity, gas and water.
Read 18 tweets
Niraparib,orally active small molecule PARP inhibitor developed by Tesaro to Rx ovarian cancer, granted fast track designtn by USFDA in 2016
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
Dishman Carbogen makes the API for the drug, has been supplying APIs to GSK from 2017
The approval will help Niraparib grow multifold,big positive for Dishman’s CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumors have completely or partially responded to platinum-based chemotherapy treatments
Zejula sales $295 million 2019
Read 4 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!